Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cardiovascular Drugs and Therapy
Erschienen in: Cardiovascular Drugs and Therapy 2/2019

07.03.2019 | REVIEW ARTICLE

The Role of Thyroid Hormones in Heart Failure

verfasst von: Catarina Vale, João Sérgio Neves, Madalena von Hafe, Marta Borges-Canha, Adelino Leite-Moreira

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Cardiovascular diseases are the leading cause of death worldwide. Heart failure is the terminal manifestation of cardiovascular diseases, and its morbidity and mortality remain high. The prevalence of heart failure with preserved ejection fraction (HFpEF) among heart failure patients remains uncertain. However, recent studies have found that it ranged from 40 to 71%. There is still no effective treatment for HFpEF. Thyroid hormones (TH) have central regulatory actions in the cardiovascular system, particularly in the heart. Changes in plasmatic or tissue thyroid hormone levels are associated with significant alterations in cardiovascular function. A significant proportion of patients with heart failure presents some form of thyroid dysfunction including hypothyroidism, hyperthyroidism, and low T3 syndrome. Furthermore, thyroid hormones can vary at a local level independently of the serum TH levels. This may lead to local cardiac hypothyroidism in heart failure. Based on these findings and the role that TH play in cardiovascular regulation, they were proposed as a potential target for heart failure therapy. Several clinical and experimental studies have shown beneficial effects of TH supplementation. Data from epidemiological studies supports a higher risk of heart failure and a worse prognosis in heart failure patients with low levels of TH. In addition, animal studies and small clinical studies suggest that TH supplementation may improve cardiac function in heart failure. Although further studies are needed to evaluate the safety and efficacy of TH in this context, the available evidence suggests that TH modulation is a promising therapeutic approach to heart failure.
Literatur
1.
World Health Organization. Reducing risks, promoting healthy life. The world health report 2002;Geneva: WHO.
2.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810–52.CrossRefPubMed
3.
Ceia F, Fonseca C, Mota T, Morais H, Matias F, de Sousa A, et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail. 2002;4(4):531–9.CrossRefPubMed
4.
Cortina A, Reguero J, Segovia E, Rodriguez Lambert JL, Cortina R, Arias JC, et al. Prevalence of heart failure in Asturias (a region in the north of Spain). Am J Cardiol. 2001;87(12):1417–9.CrossRefPubMed
5.
Devereux RB, Roman MJ, Liu JE, Welty TK, Lee ET, Rodeheffer R, et al. Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study. Am J Cardiol. 2000;86(10):1090–6.CrossRefPubMed
6.
Hedberg P, Lonnberg I, Jonason T, Nilsson G, Pehrsson K, Ringqvist I. Left ventricular systolic dysfunction in 75-year-old men and women; a population-based study. Eur Heart J. 2001;22(8):676–83.CrossRefPubMed
7.
Kitzman DW, Gardin JM, Gottdiener JS, Arnold A, Boineau R, Aurigemma G, et al. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol. 2001;87(4):413–9.CrossRefPubMed
8.
Kupari M, Lindroos M, Iivanainen AM, Heikkila J, Tilvis R. Congestive heart failure in old age: prevalence, mechanisms and 4-year prognosis in the Helsinki Ageing Study. J Intern Med. 1997;241(5):387–94.CrossRefPubMed
9.
Morgan S, Smith H, Simpson I, Liddiard GS, Raphael H, Pickering RM, et al. Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in general practice setting: cross sectional survey. BMJ. 1999;318(7180):368–72.CrossRefPubMedPubMedCentral
10.
Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289(2):194–202.CrossRefPubMed
11.
Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A, et al. Prevalence of heart failure and left ventricular dysfunction in the general population; the Rotterdam Study. Eur Heart J. 1999;20(6):447–55.CrossRefPubMed
12.
Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis. 2005;47(5):320–32.CrossRefPubMed
13.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.CrossRefPubMed
14.
Laurberg P. Mechanisms governing the relative proportions of thyroxine and 3,5,3′-triiodothyronine in thyroid secretion. Metabolism. 1984;33(4):379–92.CrossRefPubMed
15.
Hannoush ZC, Weiss RE. Thyroid hormone replacement in patients following thyroidectomy for thyroid cancer. Rambam Maimonides Med J. 2016;7(1).
16.
Abdalla SM, Bianco AC. Defending plasma T3 is a biological priority. Clin Endocrinol. 2014;81(5):633–41.CrossRef
17.
Korevaar TI, Steegers EA, Pop VJ, Broeren MA, et al. Thyroid autoimmunity impairs the thyroidal response to human chorionic gonadotropin: two population-based prospective cohort studies. J Clin Endocrinol Metab. 2017;102(1):69–77.PubMed
18.
Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002;23(1):38–89.CrossRef
19.
Salvatore D, Bartha T, Harney JW, Larsen PR. Molecular biological and biochemical characterization of the human type 2 selenodeiodinase. Endocrinology. 1996;137(8):3308–15.CrossRef
20.
Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure. Circulation. 2010;122(4):385–93.CrossRefPubMed
21.
Olivares EL, Carvalho DP. Thyroid hormone metabolism in heart failure: iodothyronine deiodinases in focus. Curr Opin Endocrinol Diabetes Obes. 2010;17(5):414–7.CrossRefPubMed
22.
23.
Jabbar A, Pingitore A, Pearce SH, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol. 2017;14(1):39–55.CrossRefPubMed
24.
25.
Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344(7):501–9.CrossRefPubMed
26.
Kaasik A, Paju K, Vetter R, Seppet EK. Thyroid hormones increase the contractility but suppress the effects of β-adrenergic agonist by decreasing phospholamban expression in rat atria. Cardiovasc Res. 1997;35(1):106–12.CrossRefPubMed
27.
Holt E, Sjaastad I, Lunde PK, Christensen G, Sejersted OM. Thyroid hormone control of contraction and the Ca(2+)-ATPase/phospholamban complex in adult rat ventricular myocytes. J Mol Cell Cardiol. 1999;31(3):645–56.CrossRefPubMed
28.
He H, Giordano FJ, Hilal-Dandan R, Choi DJ, Rockman HA, McDonough PM, et al. Overexpression of the rat sarcoplasmic reticulum Ca2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J Clin Invest. 1997;100(2):380–9.CrossRefPubMedPubMedCentral
29.
Yao J, Eghbali M. Decreased collagen gene expression and absence of fibrosis in thyroid hormone-induced myocardial hypertrophy. Response of cardiac fibroblasts to thyroid hormone in vitro. Circ Res. 1992;71(4):831–9.CrossRefPubMed
30.
Ghose Roy S, Mishra S, Ghosh G, Bandyopadhyay A. Thyroid hormone induces myocardial matrix degradation by activating matrix metalloproteinase-1. Matrix Biol. 2007;26(4):269–79.CrossRefPubMed
31.
32.
Ojamaa K, Klemperer JD, Klein I. Acute effects of thyroid hormone on vascular smooth muscle. Thyroid. 1996;6(5):505–12.CrossRefPubMed
33.
Park KW, Dai HB, Ojamaa K, Lowenstein E, Klein I, Sellke FW. The direct vasomotor effect of thyroid hormones on rat skeletal muscle resistance arteries. Anesth Analg. 1997;85(4):734–8.CrossRefPubMed
34.
Kuzman JA, Gerdes AM, Kobayashi S, Liang Q. Thyroid hormone activates Akt and prevents serum starvation-induced cell death in neonatal rat cardiomyocytes. J Mol Cell Cardiol. 2005;39(5):841–4.CrossRefPubMed
35.
Silva JE. Thyroid hormone control of thermogenesis and energy balance. Thyroid. 1995;5(6):481–92.CrossRefPubMed
36.
Danzi S, Klein I. Thyroid hormone and blood pressure regulation. Curr Hypertens Rep. 2003;5(6):513–20.CrossRefPubMed
37.
38.
Schmidt-Ott UM, Ascheim DD. Thyroid hormone and heart failure. Curr Heart Fail Rep. 2006;3(3):114–9.CrossRefPubMed
39.
Biondi B. Mechanisms in endocrinology: heart failure and thyroid dysfunction. Eur J Endocrinol. 2012;167(5):609–18.CrossRefPubMed
40.
Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA. 2005;294(1):71–80.CrossRefPubMed
41.
Delitala AP, Filigheddu F, Orru M, AlGhatrif M, Steri M, Pilia MG, et al. No evidence of association between subclinical thyroid disorders and common carotid intima medial thickness or atherosclerotic plaque. Nutr Metab Cardiovasc Dis. 2015;25(12):1104–10.CrossRefPubMedPubMedCentral
42.
Volzke H, Robinson DM, Schminke U, Ludemann J, Rettig R, Felix SB, et al. Thyroid function and carotid wall thickness. J Clin Endocrinol Metab. 2004;89(5):2145–9.CrossRefPubMed
43.
Delitala AP, Orru M, Filigheddu F, Pilia MG, Delitala G, Ganau A, et al. Serum free thyroxine levels are positively associated with arterial stiffness in the SardiNIA study. Clin Endocrinol. 2015;82(4):592–7.CrossRef
44.
Volzke H, Ittermann T, Schmidt CO, Dorr M, John U, Wallaschofski H, et al. Subclinical hyperthyroidism and blood pressure in a population-based prospective cohort study. Eur J Endocrinol. 2009;161(4):615–21.CrossRefPubMed
45.
Dorr M, Robinson DM, Wallaschofski H, Schwahn C, John U, Felix SB, et al. Low serum thyrotropin is associated with high plasma fibrinogen. J Clin Endocrinol Metab.
46.
Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet. 2001;358(9285):861–5.CrossRefPubMed
47.
Iervasi G, Molinaro S, Landi P, Taddei MC, Galli E, Mariani F, et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med. 2007;167(14):1526–32.CrossRefPubMed
48.
Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012;172(10):799–809.CrossRefPubMed
49.
Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FD, Wilson S, et al. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med. 2007;167(9):928–34.CrossRefPubMed
50.
Auer J, Eber B. Subclinical hyperthyroidism and atrial fibrillation. Acta Med Austriaca. 2003;30(4):98–9.PubMed
51.
52.
Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006;295(9):1033–41.CrossRefPubMedPubMedCentral
53.
Rodondi N, Bauer DC, Cappola AR, Cornuz J, Robbins J, Fried LP, et al. Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health study. J Am Coll Cardiol. 2008;52(14):1152–9.CrossRefPubMedPubMedCentral
54.
Biondi B, Palmieri EA, Fazio S, Cosco C, Nocera M, Sacca L, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab. 2000;85(12):4701–5.PubMed
55.
Biondi B, Bartalena L, Cooper DS, Hegedus L, Laurberg P, Kahaly GJ. The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J. 2015;4(3):149–63.CrossRefPubMedPubMedCentral
56.
Kisso B, Patel A, Redetzke R, Gerdes AM. Effect of low thyroid function on cardiac structure and function in spontaneously hypertensive heart failure rats. J Card Fail. 2008;14(2):167–71.CrossRefPubMedPubMedCentral
57.
58.
Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab. 2003;88(6):2438–44.CrossRefPubMed
59.
Biondi B, Fazio S, Palmieri EA, Carella C, Panza N, Cittadini A, et al. Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. J Clin Endocrinol Metab. 1999;84(6):2064–7.CrossRefPubMed
60.
Monzani F, Di Bello V, Caraccio N, Bertini A, Giorgi D, Giusti C, et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. J Clin Endocrinol Metab. 2001;86(3):1110–5.CrossRefPubMed
61.
Ripoli A, Pingitore A, Favilli B, Bottoni A, Turchi S, Osman NF, et al. Does subclinical hypothyroidism affect cardiac pump performance? Evidence from a magnetic resonance imaging study. J Am Coll Cardiol. 2005;45(3):439–45.CrossRefPubMed
62.
Owen PJ, Sabit R, Lazarus JH. Thyroid disease and vascular function. Thyroid. 2007;17(6):519–24.CrossRefPubMed
63.
Peixoto de Miranda EJ, Bittencourt MS, Pereira AC, Goulart AC, Santos IS, Lotufo PA, et al. Subclinical hypothyroidism is associated with higher carotid intima-media thickness in cross-sectional analysis of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Nutr Metab Cardiovas Dis. 2016;26(10):915–21.CrossRef
64.
Lambrinoudaki I, Armeni E, Rizos D, Georgiopoulos G, Kazani M, Alexandrou A, et al. High normal thyroid-stimulating hormone is associated with arterial stiffness in healthy postmenopausal women. J Hypertens. 2012;30(3):592–9.CrossRefPubMed
65.
Wang J, Zheng X, Sun M, Wang Z, Fu Q, Shi Y, et al. Low serum free thyroxine concentrations associate with increased arterial stiffness in euthyroid subjects: a population-based cross-sectional study. Endocrine. 2015;50(2):465–73.CrossRefPubMed
66.
Rodondi N, Newman AB, Vittinghoff E, de Rekeneire N, Satterfield S, Harris TB, et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med. 2005;165(21):2460–6.CrossRefPubMed
67.
Boekholdt SM, Titan SM, Wiersinga WM, Chatterjee K, Basart DC, Luben R, et al. Initial thyroid status and cardiovascular risk factors: the EPIC-Norfolk prospective population study. Clin Endocrinol. 2010;72(3):404–10.CrossRef
68.
McQuade C, Skugor M, Brennan DM, Hoar B, Stevenson C, Hoogwerf BJ. Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: a PreCIS database study. Thyroid. 2011;21(8):837–43.CrossRefPubMed
69.
Razvi S, Weaver JU, Vanderpump MP, Pearce SH. The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham Survey cohort. J Clin Endocrinol Metab. 2010;95(4):1734–40.CrossRefPubMed
70.
Walsh JP, Bremner AP, Bulsara MK, O'Leary P, Leedman PJ, Feddema P, et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med. 2005;165(21):2467–72.CrossRefPubMed
71.
Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304(12):1365–74.CrossRefPubMedPubMedCentral
72.
Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29(1):76–131.CrossRefPubMed
73.
Razvi S, Weaver JU, Butler TJ, Pearce SH. Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. Arch Intern Med. 2012;172(10):811–7.CrossRefPubMed
74.
Madathil A, Hollingsworth KG, Blamire AM, Razvi S, Newton JL, Taylor R, et al. Levothyroxine improves abnormal cardiac bioenergetics in subclinical hypothyroidism: a cardiac magnetic resonance spectroscopic study. J Clin Endocrinol Metab. 2015;100(4):E607–10.CrossRefPubMed
75.
Pearce SH, Brabant G, Duntas LH, Monzani F, Peeters RP, Ravzi S, et al. ETA guideline: management of subclinical hypothyroidism. Eur Thyroid J. 2013;2(4):215–28.CrossRefPubMedPubMedCentral
76.
77.
Warner MH, Beckett GJ. Mechanisms behind the non-thyroidal illness syndrome: an update. J Endocrinol. 2010;205(1):1–13.CrossRefPubMed
78.
Pappa TA, Vagenakis AG, Alevizaki M. The nonthyroidal illness syndrome in the non-critically ill patient. Eur J Clin Investig. 2011;41(2):212–20.CrossRef
79.
Kaptein EM, Sanchez A, Beale E, Chan LS. Clinical review: thyroid hormone therapy for postoperative nonthyroidal illnesses: a systematic review and synthesis. J Clin Endocrinol Metab. 2010;95(10):4526–34.CrossRefPubMed
80.
Haddady S, Alan P. Non-thyroidal illness and the management of thyroid disorders in the intensive care unit. In: Irwin RS, Rippe JM, editors. Intensive care medicine. Philadelphia: Wolters Kluwer /Lippincott Williams & Wilkins; 2011. pp. 1182–1194.
81.
Farwell AP. Thyroid hormone therapy is not indicated in the majority of patients with the sick euthyroid syndrome. Endocr Pract. 2008;14(9):1180–7.CrossRefPubMed
82.
Boelen A, Kwakkel J, Fliers E. Beyond low plasma T3: local thyroid hormone metabolism during inflammation and infection. Endocr Rev. 2011;32(5):670–93.CrossRefPubMed
83.
84.
Gerdes AM. Restoration of thyroid hormone balance: a game changer in the treatment of heart failure? Am J Physiol Heart Circ Physiol. 2015;308(1):H1–10.CrossRefPubMed
85.
Chuang CP, Jong YS, Wu CY, Lo HM. Impact of triiodothyronine and N-terminal pro-B-type natriuretic peptide on the long-term survival of critically ill patients with acute heart failure. Am J Cardiol. 2014;113(5):845–50.CrossRefPubMed
86.
Pingitore A, Landi P, Taddei MC, Ripoli A, L’Abbate A, Iervasi G. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med. 2005;118(2):132–6.CrossRefPubMed
87.
Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scarlattini M, et al. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation. 2003;107(5):708–13.CrossRefPubMed
88.
Frey A, Kroiss M, Berliner D, Seifert M, Allolio B, Guder G, et al. Prognostic impact of subclinical thyroid dysfunction in heart failure. Int J Cardiol. 2013;168(1):300–5.CrossRefPubMed
89.
D'Aloia A, Vizzardi E, Bugatti S, Rovetta R, Bonadei I, Del Magro F, et al. Effect of short-term infusive dobutamine therapy on thyroid hormone profile and hemodynamic parameters in patients with acute worsening heart failure and low-triiodothyronine syndrome. J Investig Med. 2012;60(6):907–10.CrossRefPubMed
90.
Pingitore A, Galli E, Barison A, Iervasi A, Scarlattini M, Nucci D, et al. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2008;93(4):1351–8.CrossRefPubMed
91.
Hamilton MA, Stevenson LW, Fonarow GC, Steimle A, Goldhaber JI, Child JS, et al. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol. 1998;81(4):443–7.CrossRefPubMed
92.
Fruhwald FM, Ramschak-Schwarzer S, Pichler B, Watzinger N, Schumacher M, Zweiker R, et al. Subclinical thyroid disorders in patients with dilated cardiomyopathy. Cardiology. 1997;88(2):156–9.CrossRefPubMed
93.
Hamilton MA, Stevenson LW, Luu M, Walden JA. Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol. 1990;16(1):91–5.CrossRefPubMed
94.
Opasich C, Pacini F, Ambrosino N, Riccardi PG, Febo O, Ferrari R, et al. Sick euthyroid syndrome in patients with moderate-to-severe chronic heart failure. Eur Heart J. 1996;17(12):1860–6.CrossRefPubMed
95.
Selvaraj S, Klein I, Danzi S, Akhter N, Bonow RO, Shah SJ. Association of serum triiodothyronine with B-type natriuretic peptide and severe left ventricular diastolic dysfunction in heart failure with preserved ejection fraction. Am J Cardiol. 2012;110(2):234–9.CrossRefPubMedPubMedCentral
96.
Pantos C, Dritsas A, Mourouzis I, Dimopoulos A, Karatasakis G, Athanassopoulos G, et al. Thyroid hormone is a critical determinant of myocardial performance in patients with heart failure: potential therapeutic implications. Eur J Endocrinol. 2007;157(4):515–20.CrossRefPubMed
97.
Ascheim DD, Hryniewicz K. Thyroid hormone metabolism in patients with congestive heart failure: the low triiodothyronine state. Thyroid. 2002;12(6):511–5.CrossRefPubMed
98.
Kinugawa K, Yonekura K, Ribeiro RC, Eto Y, Aoyagi T, Baxter JD, et al. Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ Res. 2001;89(7):591–8.CrossRefPubMed
99.
Pantos C, Mourouzis I, Saranteas T, Paizis I, Xinaris C, Malliopoulou V, et al. Thyroid hormone receptors alpha1 and beta1 are downregulated in the post infarcted rat heart: consequences on the response to ischaemia-reperfusion. Basic Res Cardiol. 2005;100(5):422–32.CrossRefPubMed
100.
Henderson KK, Danzi S, Paul JT, Leya G, Klein I, Samarel AM. Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure. Circ Heart Fail. 2009;2(3):243–52.CrossRefPubMed
101.
Roos A, Links TP, Wolffenbuttel BH. Subclinical thyroid disease and heart failure. Eur J Heart Fail. 2014;16(2):119–21.CrossRefPubMed
102.
Weltman NY, Pol CJ, Zhang Y, Wang Y, Koder A, Raza S, et al. Long-term physiological T3 supplementation in hypertensive heart disease in rats. Am J Physiol Heart Circ Physiol. 2015;309(6):H1059–65.CrossRefPubMedPubMedCentral
103.
Trivieri MG, Oudit GY, Sah R, Kerfant BG, Sun H, Gramolini AO, et al. Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction. Proc Natl Acad Sci U S A. 2006;103(15):6043–8.CrossRefPubMedPubMedCentral
104.
Gerdes AM, Kellerman SE, Malec KB, Schocken DD. Transverse shape characteristics of cardiac myocytes from rats and humans. Cardioscience. 1994;5(1):31–6.PubMed
105.
Thomas TA, Kuzman JA, Anderson BE, Andersen SM, Schlenker EH, Holder MS, et al. Thyroid hormones induce unique and potentially beneficial changes in cardiac myocyte shape in hypertensive rats near heart failure. Am J Physiol Heart Circ Physiol. 2005;288(5):H2118–22.CrossRefPubMed
106.
Ito K, Kagaya Y, Shimokawa H. Thyroid hormone and chronically unloaded hearts. Vasc Pharmacol. 2010;52(3–4):138–41.CrossRef
107.
Kinugasa Y, Yamamoto K. Subclinical hypothyroidism as a new therapeutic target for patients with heart failure with preserved ejection fraction. Circ J. 2014;78(6):1333–4.CrossRefPubMed
108.
Zhang Y, Dedkov EI, Lee B 3rd, Li Y, Pun K, Gerdes AM. Thyroid hormone replacement therapy attenuates atrial remodeling and reduces atrial fibrillation inducibility in a rat myocardial infarction-heart failure model. J Card Fail. 2014;20(12):1012–9.CrossRefPubMedPubMedCentral
109.
Khalife WI, Tang YD, Kuzman JA, Thomas TA, Anderson BE, Said S, et al. Treatment of subclinical hypothyroidism reverses ischemia and prevents myocyte loss and progressive LV dysfunction in hamsters with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005;289(6):H2409–15.CrossRefPubMed
110.
Holmager P, Schmidt U, Mark P, Andersen U, Dominguez H, Raymond I, et al. Long-term L-triiodothyronine (T3) treatment in stable systolic heart failure patients: a randomised, double-blind, cross-over, placebo-controlled intervention study. Clin Endocrinol. 2015;83(6):931–7.CrossRef
111.
Gerdes AM. Restoration of thyroid hormone balance: a game-changer in the treatment of heart failure? Am J Physiol Heart Circ Physiol. 2015;308(1):H1–10.CrossRefPubMed
112.
Nuovo J, Ellsworth A, Christensen DB, Reynolds R. Excessive thyroid hormone replacement therapy. J Am Board Fam Pract. 1995;8(6):435–9.PubMed
113.
Biondi B, Fazio S, Carella C, Amato G, Cittadini A, Lupoli G, et al. Cardiac effects of long-term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1993;77(2):334–8.PubMed
114.
Wartofsky L. Osteoporosis, a growing concern for the thyroidologist. Thyroid Today. 1988;11:1–11.
115.
Tribulova N, Knezi V, Shainberg A, Seki S, Soukup T. Thyroid hormones and cardiac arrhythmias. Vasc Pharmacol. 2010;52(3–4):102–12.CrossRef
Metadaten
Titel
The Role of Thyroid Hormones in Heart Failure
verfasst von
Catarina Vale
João Sérgio Neves
Madalena von Hafe
Marta Borges-Canha
Adelino Leite-Moreira
Publikationsdatum
07.03.2019
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 2/2019
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-019-06870-4

Weitere Artikel der Ausgabe 2/2019

Cardiovascular Drugs and Therapy 2/2019 Zur Ausgabe

ORIGINAL ARTICLE

GATA4-Twist1 Signalling in Disturbed Flow-Induced Atherosclerosis

ORIGINAL ARTICLE

High-Density Lipoprotein Function and Dysfunction in Health and Disease

ORIGINAL ARTICLE

Improved Long-term Survival with Remote Limb Ischemic Preconditioning in a Rat Fixed-Pressure Hemorrhagic Shock Model

ORIGINAL ARTICLE

Emerging Roles of Sympathetic Nerves and Inflammation in Perivascular Adipose Tissue

ORIGINAL ARTICLE

Activation of T Lymphocytes as a Novel Mechanism in Beta1-Adrenergic Receptor Autoantibody-Induced Cardiac Remodeling

EditorialNotes

Special Issue: British Society for Cardiovascular Research

Neu im Fachgebiet Kardiologie

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Prävention und Rehabilitation in der Kardiologie | Nachrichten

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation
weitere anzeigen

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen